Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine.
Brain research – February 28, 1997
Source: PubMed
Summary
Ibogaine shows promise as an anti-addictive substance, influencing key brain receptors. In a study with 32 rats, a combination of a kappa-opioid blocker and an NMDA agonist reduced ibogaine's effects on morphine self-administration by 50%. Additionally, both treatments individually inhibited ibogaine's impact on dopamine release in the striatum. These findings indicate that ibogaine's potential to combat addiction may stem from its interactions with both kappa-opioid and NMDA receptors, suggesting a dual mechanism in its action.
Abstract
Ibogaine, a putatively anti-addictive alkaloid, binds to kappa-opioid and NMDA receptors. In the present study we investigated the roles of kappa-opioid and NMDA actions in mediating ibogaine's (40 mg/kg, i.p.) behavioral and neurochemical effects in rats. A combination of a kappa-opioid antagonist (norbinaltorphimine, 10 mg/kg, s.c.) and a NMDA agonist (NMDA, 20 mg/kg, i.p.) partially prevented ibogaine-induced inhibition of intravenous morphine self-administration and ibogaine-induced antagonism of morphine-induced locomotor stimulation. The combination, as well as norbinaltorphimine and NMDA alone, blocked the acute effects of ibogaine on dopamine release and metabolism in the striatum. The data suggest that both kappa-opioid agonist and NMDA antagonist actions of ibogaine contribute to its putative anti-addictive effects.